CCL5 and cancer: It has been shown that CX3CR1+ monocytes are recruited to the tumor cell aggregates in response to tumor-derived CX3CL1, where they can directly engage cancer cells or secrete CCL3, CCL4 and CCL5 to activate natural killer cells to kill CTCs (125).